⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460070 | 0.88 | MAPK1 (0.33) | — | |
| SCHEMBL25309553 | 0.75 | — | — | |
| SCHEMBL518682 | 0.69 | — | — | |
| SCHEMBL28475397 | 0.68 | — | — | |
| SCHEMBL23546150 | 0.67 | MAPK1 (0.33) | — | |
| SCHEMBL1766234 | 0.67 | — | — | |
| SCHEMBL2258059 | 0.67 | MAPK1 (0.32) | — | |
| SCHEMBL16268803 | 0.65 | — | — | |
| SCHEMBL19523874 | 0.64 | MAPK1 (0.30) | — | |
| SCHEMBL21271343 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122036736-A | Pyrrolo [2,3-d ] pyrimidine derivative, synthetic method and application | 云南大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4739688-A2 | TRIAZOLO WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| CN-116917280-B | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12617795-B2 | Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators | ASTRAZENECA AB (SE) | 2026-05-05 | — | — | US | disclosed |
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4727942-A2 | THIAZOLOPYRIDIN-7(4H)-ONE WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4692088-A1 | COMPOUND ACTING AS WRN HELICASE INHIBITOR | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025217420-A1 | PYRIDINONE COMPOUNDS, METHODS AND USES THEREOF | ZENO MANAGEMENT, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2010135560-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| CN-101489989-A | Pentadiene amide derivative | KYOWA HAKKO KIRIN CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-1587799-B1 | BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2004063177-A1 | BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-29 | — | — | WO | disclosed |